Latest News

While Apex Investment PSC ( ADX:APEX ) shareholders are probably generally happy, the stock hasn't had particularly...

Key Insights Significant control over Techno Electric & Engineering by private companies implies that the general...

When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 24x, you may consider...

Transworld Shipping Lines Limited's ( NSE:TRANSWORLD ) price-to-sales (or "P/S") ratio of 0.9x might make it look like...

With its stock down 19% over the past three months, it is easy to disregard Sanghvi Movers (NSE:SANGHVIMOV). However, a...

In its latest quarter, AdaptHealth reported US$820.3 million in revenue, a 1.8% year-on-year increase that surpassed analyst estimates by 2.5%, with full-year revenue guidance matching expectations despite sector labor and reimbursement pressures. Although this was the slowest revenue growth among its senior health and home care peers, AdaptHealth’s ability to beat forecasts and reaffirm guidance highlights a measure of resilience in a challenging home-based care landscape. Next, we’ll...

Why Boston Scientific’s upcoming earnings are in focus Boston Scientific (BSX) is back on investor radar as the company approaches its next earnings release, with analysts lifting earnings estimates and pointing to solid demand in electrophysiology and structural heart procedures. See our latest analysis for Boston Scientific. At a share price of US$97.64, Boston Scientific has seen a 5.33% 1 month share price return and a 109.84% 3 year total shareholder return. This suggests underlying...

Recent supply chain improvements and new multi year agreements for zero emission battery electric and hydrogen fuel cell buses have pushed NFI Group (TSX:NFI) back into focus for investors who are assessing its recovery story. See our latest analysis for NFI Group. The recent supply chain relief and zero emission bus agreements sit against a share price of CA$16.11, with a 30 day share price return of 20.22% and a 1 year total shareholder return of 17.94%. This suggests that momentum has been...

AbCellera Biologics (ABCL) has drawn fresh attention after settling a dispute with Bruker Corporation that brings in a US$36 million upfront payment plus future royalties, and it has also added scientist Stephen Quake to its board. See our latest analysis for AbCellera Biologics. The recent legal settlement and board appointment come on the back of a 7 day share price return of 27.41% and a year to date share price return of 27.41%. The 1 year total shareholder return of 49.66% contrasts with...

In recent weeks, Sysco Canada was named one of Atlantic Canada's Best Places to Work 2026, while Sysco Los Angeles began distributing Beyond Oil's product, and Sysco expanded its sustainability efforts through a partnership with Welgro Produce to support local growers. Together, these developments highlight how Sysco is combining workplace culture, product innovation, and supply-chain sustainability to reinforce its role in the foodservice ecosystem. We’ll now explore how Sysco’s new...

It is hard to get excited after looking at Roto Pumps' (NSE:ROTO) recent performance, when its stock has declined 15...

If you are wondering whether Salesforce shares are offering fair value right now, you are not alone. Many investors are asking the same question after recent price moves. The stock last closed at US$259.94, with returns of 2.5% over the past week, a 1.6% decline over 30 days, 2.5% year to date, a 17.7% decline over 1 year and a 76.0% and 23.4% return over 3 and 5 years respectively. Recent attention on Salesforce has centered on how the company is positioning its platform and tools within...

In recent days, Silvercorp Metals has remained in a consolidation phase as investors reassess silver prices, Chinese growth prospects, and regulatory risk, while the company continues to emphasize low operating costs, operational efficiency, and ongoing exploration progress. At the same time, rising retail interest in silver has turned Silvercorp into a higher-risk, leveraged way to access precious metals exposure, amplifying the impact of shifting sentiment around both silver prices and...

Recently, Thor Industries highlighted ongoing headwinds from a cooler recreational vehicle cycle, elevated interest rates, and uneven consumer demand that are pressuring its business conditions. An interesting twist is management’s use of pragmatic pricing in a highly competitive market, which could weigh on near-term margins as dealers keep inventories tight. With these pressures on RV demand and pricing in mind, we’ll now examine how the recent developments shape Thor Industries’...

If you are wondering whether Viking Therapeutics is still priced for promise or if the recent excitement has cooled enough to offer better value, this article walks you through what the current price might be implying. The stock has recently given back some ground, with a 9.7% decline over the last week, a 14.8% decline over the last month, and an 18.6% decline over the past year. The 3-year and 5-year returns sit at 257.4% and 393.7% respectively. These moves sit against a backdrop of...

The Trump administration previously took a 10% equity stake in Trilogy Metals and issued an executive order authorizing construction of an access road to Alaska’s Ambler Mining District, unlocking physical access to the mineral-rich Upper Kobuk Mineral Projects that Trilogy partly owns. This combination of government ownership and infrastructure support is unusual, effectively tying Trilogy’s future project development to US critical-minerals supply chain priorities. We’ll now examine how...

In recent days, UBS initiated coverage on IDEAYA Biosciences and the company reported full enrollment of its pivotal Phase 2/3 darovasertib trial in metastatic uveal melanoma, while GlaxoSmithKline opted to end their collaboration and return the Werner Helicase and Pol Theta programs by March 2026. This combination of fresh analyst attention, approaching pivotal data, and regained control of key oncology assets reshapes how investors may view IDEAYA’s pipeline breadth and future...

If you are wondering whether Yum! Brands at around US$155 a share is still good value after its recent run, you are not alone. The stock has returned 3.3% over the last week, 5.0% over the last month, 3.3% year to date and 28.6% over the past year, with a 5 year return of 60.1%. Recent attention on Yum! Brands has focused on how its global fast food brands fit into consumer spending trends and how investors are weighing that against other consumer services stocks. This backdrop helps explain...

What the WDSF partnership could mean for Atos shares Atos (ENXTPA:ATO) has drawn fresh attention after announcing a partnership with the World DanceSport Federation, focused on digital ticketing, competition services, data insights, and fan engagement across upcoming international DanceSport events. For investors, this agreement highlights how Atos is applying its digital and data capabilities in a niche global sports setting. It offers another reference point when weighing the stock against...

In recent days, Mondelez International has moved to review its U.S. creative agencies following the appointment of Travis Freeman as senior vice president and global head of consumer experience, while investors focus on its soon-to-be-reported fourth-quarter results against a backdrop of higher input costs and softer demand. This combination of a fresh marketing leadership direction and upcoming earnings has sharpened attention on how Mondelez positions its brands and manages cost...

Carter’s, Inc. recently appointed David B. Tichiaz as Chief Brand Officer, placing him in charge of product design and merchandising after leadership roles at Stance and Vans. This hire brings fresh apparel and lifestyle brand expertise that could influence how Carter’s refreshes its product offering while it continues to close lower-margin stores. Now we’ll explore how bringing in a seasoned lifestyle brand leader to oversee design and merchandising could reshape Carter’s broader investment...

Barclays’ upgrade of Lowe's Companies (LOW) to overweight puts fresh attention on the retailer, as the bank points to valuation, pent up demand, housing trends, and tax policy as key drivers. See our latest analysis for Lowe's Companies. At a share price of US$267.21, Lowe's has seen momentum build recently, with a 1 day share price return of 4.29% and a 90 day share price return of 15.07%. The 5 year total shareholder return of 70.99% points to meaningful long term value creation. If this...

In early January 2026, Krystal Biotech reported a positive interim update from the highest-dose cohort of its Phase 1 CORAL-1 study of inhaled gene therapy KB407 in cystic fibrosis, confirming successful lung delivery and expression of wild-type CFTR protein with generally mild to moderate side effects and one procedure-related serious adverse event that resolved. The company also disclosed that it has submitted the design of its repeat-dosing CORAL-3 study to the US FDA, aiming to advance...

If you are wondering whether Nextpower's recent share price puts it at a bargain or a stretch, you are not alone. This article will walk through what the current price might be implying. Nextpower shares closed at US$91.17, with a 121.8% return over the last year, a 2.0% gain over the past month, and a 1.7% decline over the last week. This has naturally raised questions about how the market is weighing its potential against its risks. Recent coverage has focused on Nextpower's position in...